Opthea Ltd Logo

Opthea Ltd

Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.

OPT | US

Overview

Corporate Details

ISIN(s):
US68386J2087
LEI:
Country:
United States of America
Address:
LEVEL 4, 3141 SOUTH YARRA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Opthea Ltd. is a clinical-stage biopharmaceutical company that was focused on developing novel therapies for vision-threatening retinal diseases. The company's primary development program centered on its lead candidate, sozinibercept (OPT-302), a first-in-class biologic inhibitor of VEGF-C and VEGF-D. Sozinibercept was being evaluated in combination with standard-of-care anti-VEGF-A therapies for the treatment of wet age-related macular degeneration (wet AMD), with the goal of delivering superior visual outcomes. However, in March 2025, the company announced that its pivotal Phase 3 clinical trials (COAST and ShORe) did not meet their primary endpoints, leading to the discontinuation of the development program and significant corporate restructuring.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Opthea Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Opthea Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Opthea Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Merus N.V. Logo
Develops multispecific antibody therapies that harness the immune system to fight cancer.
United States of America
MRUS
MESOBLAST LTD Logo
Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.
United States of America
MESO
Metagenomi, Inc. Logo
Discovering novel gene editing tools from nature for curative genetic medicines.
United States of America
MGX
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America
MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America
MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea
140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea
432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America
MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America
MDXG
Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America
MNMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.